Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Testosterone Treatment Lawsuits More Than Doubled Last Month As The FDA Continues To Investigate Risks
  • USA - English


News provided by

Wright & Schulte LLC

Jul 07, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Testosterone Treatment Lawsuits More Than Doubled Last Month
Testosterone Treatment Lawsuits More Than Doubled Last Month

If your believe you have suffered cardiovascular problems due to Androgel, Testim, Androderm or other Testosterone Treatment Drugs Call Wright & Schulte today for a Free Legal Evaluation at 1-800-399-0795 or by visiting www.yourlegalhelp.com

Post this

Columbus, OH (PRWEB) July 07, 2014 -- Testosterone treatment lawsuits continue to mount as the number of filing has double in the last month. Wright & Schulte LLC notes that as of June 16th, there are 98 testosterone lawsuits filed against the makers of Androgel, Androderm, Testim and Depo pending under MDL 2545 in the U.S. District Court of Illinois. All of the testosterone therapy complaints allege taking one or more testosterone replacement drugs caused them to experience strokes, heart attacks, blood clots, and other cardiac and blood clot issues. The attorneys are concerned with the rate the number of Testosterone complaints is growing since there were 45 Testosterone lawsuits pending on June 6th when a panel of federal judges issued an order to transfer the low testosterone claims to the U.S. District Court, Northern District of Illinois. That is more than double in about 10 days. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)
[jpml.uscourts.gov/sites/jpml/files/MDL-2545-
Initial_Transfer-05-14.pdf]
[jpml.uscourts.gov/sites/jpml/files/
Pending_MDL_Dockets_By_District-June-16-2014.pdf]

With the growing number of testosterone treatment lawsuits, the firm is actively investigating the side-effects of testosterone treatment drugs and continues to offer free legal evaluations to men or families of men who believe they have suffered cardiac events due to testosterone therapy drugs such as AndroGel, Androderm, and Testim. To speak with an experienced attorney regarding your legal option contact Wright & Schulte LLC by calling 1-800-399-0795 or visit yourlegalhelp.com. You can also follow us on Facebook and Like us on Twitter for all the news on testosterone treatment products and other harmful drugs.

According to court records, testosterone treatment lawsuit filings began in January after the U.S. Food & Drug Administration (FDA) announced it was launching an investigation into the safety of prescription testosterone products taken by men who suffer from hypogonadism (low testosterone). The FDA's re-evaluation of low testosterone medication was triggered by a review of two observational studies. The first study, published in the PLOS One Journal on January 29, 2014, found that men over 65 and younger men with a pre-existing heart disease who used prescribed testosterone drugs were at a greater risk of having a heart attack within the first 90 days after taking the medication for the first time. The second study, published in the November 2013 Journal of the American Medical Association, found that older men who had underlying cardiovascular disease and took low testosterone treatment had a 30 percent increased risk of having a stroke, heart attack or death compared to men who did not take the medication.
[fda.gov/Drugs/DrugSafety/ucm383904.htm, January 31, 2014]
[plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0085805, January 29, 2014]
[jama.jamanetwork.com/article.aspx?articleid=1764051, November 6, 2013]

Two weeks after the judicial panel consolidated all testosterone lawsuits pending across the country, the FDA ordered testosterone manufacturers to include a general warning about the risk of venous blood clots on their drug labels. The federal regulator acknowledged that drug labels already include the risk of blood clots in veins as a consequence of polycythemia, an abnormal increase in the number of red blood cells that sometimes occurs with testosterone treatment. According to the FDA, post-market reports have shown that blood clots are occurring that are unrelated to polycythemia. Because of this development, the federal agency said in its June 19th safety alert that it wants the labeling on all FDA-approved testosterone products to be consistent in including a general warning about the risk of venous blood clots.
[fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm402054.htm, June 20, 2014]
[fda.gov/Drugs/DrugSafety/ucm401746.htm, June 19, 2014]

In the wake of the FDA’s announcement on the possible cardiac risks associated with low testosterone treatment drugs, doctors are complaining that research on the safety of testosterone replacement therapy is inconclusive and leaves them wondering how and whether to treat hypogonadism, according to a Los Angeles Times report. An endocrinologist quoted in the article suggests that researchers launch large, randomized clinical trials in which some men are given low testosterone medication and others are given a placebo and follow both groups for several years. The problem with existing research, according to the endocrinologist, is that it infers but does not prove that there are risks associated with testosterone medication.
[latimes.com/science/sciencenow/la-sci-sn-testosterone-supplement-debate-20140428-story.html, April 28, 2014]

Wright & Schulte LLC offers free legal consultations to men who experienced heart attack, stroke, blood clots and other side effects believed to be associated with the use of testosterone replacement therapy drugs such as AndroGel, Androderm, Testim and Depo Testosterone. To find out whether you are eligible to file your own low testosterone lawsuit, please contact the attorneys at Wright & Schulte LLC by calling 1800-399-0795 or visit yourlegalhelp.com.

Contact:
Wright & Schulte LLC
812 East National Road
Vandalia, Ohio 45377
1-800-399-0795
http://www.yourlegalhelp.com
Like us on Facebook
Follow us on Twitter
Join us on Google+

Richard Schulte, Wright & Schulte LLC, http://www.yourlegalhelp.com, +1 1-800-399-0795, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.